AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) had its target price decreased by Citigroup Inc. to $24.00 in a report published on Friday, July 7th, The Fly reports. Citigroup Inc. currently has a hold rating on the specialty pharmaceutical company’s stock.
Several other equities analysts have also commented on AMAG. BidaskClub upgraded shares of AMAG Pharmaceuticals from a hold rating to a buy rating in a research report on Thursday, July 6th. Jefferies Group LLC set a $40.00 price objective on shares of AMAG Pharmaceuticals and gave the company a buy rating in a research report on Thursday, April 20th. TheStreet lowered shares of AMAG Pharmaceuticals from a c rating to a d+ rating in a report on Friday, May 5th. Barclays PLC restated an equal weight rating and issued a $20.00 target price (down previously from $25.00) on shares of AMAG Pharmaceuticals in a report on Thursday, June 1st. Finally, Cantor Fitzgerald reaffirmed a hold rating and issued a $23.00 price target on shares of AMAG Pharmaceuticals in a research note on Monday, June 26th. Two research analysts have rated the stock with a sell rating, ten have assigned a hold rating and three have assigned a buy rating to the company’s stock. The company presently has a consensus rating of Hold and a consensus target price of $28.09.
Shares of AMAG Pharmaceuticals (NASDAQ:AMAG) traded up 6.63% on Friday, reaching $20.10. 958,235 shares of the company’s stock traded hands. The stock’s market cap is $704.40 million. AMAG Pharmaceuticals has a 52-week low of $16.00 and a 52-week high of $36.83. The firm’s 50-day moving average is $18.77 and its 200-day moving average is $21.08.
AMAG Pharmaceuticals (NASDAQ:AMAG) last issued its earnings results on Thursday, August 3rd. The specialty pharmaceutical company reported ($0.40) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.58) by $0.18. AMAG Pharmaceuticals had a negative net margin of 7.58% and a negative return on equity of 4.81%. The firm had revenue of $158.39 million during the quarter, compared to analyst estimates of $158.83 million. During the same quarter in the prior year, the business earned $1.45 earnings per share. AMAG Pharmaceuticals’s revenue for the quarter was up 24.3% on a year-over-year basis. Analysts anticipate that AMAG Pharmaceuticals will post $5.40 EPS for the current fiscal year.
ILLEGAL ACTIVITY WARNING: “Citigroup Inc. Trims AMAG Pharmaceuticals, Inc. (AMAG) Target Price to $24.00” was first published by BBNS and is the sole property of of BBNS. If you are viewing this story on another publication, it was copied illegally and reposted in violation of U.S. & international trademark and copyright laws. The legal version of this story can be viewed at https://baseballnewssource.com/markets/citigroup-inc-cuts-amag-pharmaceuticals-inc-amag-price-target-to-24-00-updated-updated-updated/1180295.html.
In other AMAG Pharmaceuticals news, SVP Julie Krop sold 4,938 shares of AMAG Pharmaceuticals stock in a transaction that occurred on Thursday, July 13th. The shares were sold at an average price of $20.00, for a total transaction of $98,760.00. Following the completion of the sale, the senior vice president now directly owns 28,336 shares in the company, valued at approximately $566,720. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Insiders own 3.80% of the company’s stock.
A number of hedge funds have recently made changes to their positions in the stock. BlackRock Inc. raised its position in AMAG Pharmaceuticals by 67,790.9% in the first quarter. BlackRock Inc. now owns 4,995,412 shares of the specialty pharmaceutical company’s stock valued at $112,647,000 after buying an additional 4,988,054 shares during the period. Vanguard Group Inc. raised its position in AMAG Pharmaceuticals by 6.1% in the first quarter. Vanguard Group Inc. now owns 3,085,348 shares of the specialty pharmaceutical company’s stock valued at $69,576,000 after buying an additional 176,832 shares during the period. State Street Corp raised its position in AMAG Pharmaceuticals by 75.2% in the first quarter. State Street Corp now owns 2,522,059 shares of the specialty pharmaceutical company’s stock valued at $56,876,000 after buying an additional 1,082,366 shares during the period. LSV Asset Management raised its position in AMAG Pharmaceuticals by 34.0% in the first quarter. LSV Asset Management now owns 1,685,098 shares of the specialty pharmaceutical company’s stock valued at $37,998,000 after buying an additional 427,238 shares during the period. Finally, Acadian Asset Management LLC raised its position in AMAG Pharmaceuticals by 777.8% in the first quarter. Acadian Asset Management LLC now owns 1,226,690 shares of the specialty pharmaceutical company’s stock valued at $27,659,000 after buying an additional 1,086,937 shares during the period.
About AMAG Pharmaceuticals
AMAG Pharmaceuticals, Inc is a pharmaceutical company. The Company’s segment is the manufacture, development and commercialization of products and services for use in treating various conditions, with a focus on maternal health, anemia management and cancer supportive care. Its offerings focus on maternal health, anemia management and cancer supportive care, including its product, Makena (hydroxyprogesterone caproate injection); services related to the collection, processing and storage of umbilical cord blood stem cell and cord tissue units operated through Cord Blood Registry (CBR); its product, Feraheme (ferumoxytol), for intravenous (IV) use, and MuGard Mucoadhesive Oral Wound Rinse.
Receive News & Ratings for AMAG Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AMAG Pharmaceuticals Inc. and related companies with our FREE daily email newsletter.